Unicycive Therapeutics, Inc.
UNCY
$4.44
-$0.31-6.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.54% | 58.85% | -20.25% | 18.07% | 20.68% |
| Total Depreciation and Amortization | 59.64% | -46.65% | 50.70% | 54.10% | 61.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 304.84% | -186.18% | -32.45% | -127.95% | -119.79% |
| Change in Net Operating Assets | -291.73% | -342.42% | -359.14% | 54.80% | 506.78% |
| Cash from Operations | -53.09% | -49.01% | -56.29% | -32.81% | -13.46% |
| Capital Expenditure | -161.54% | -355.56% | -500.00% | -316.67% | -116.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -161.54% | -355.56% | -500.00% | -316.67% | -116.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -100.00% | 65.62% | 65.62% | 65.62% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 100.00% | -- | -- | -- | -- |
| Other Financing Activities | 75.12% | 90.47% | -69.88% | -49.93% | -48.90% |
| Cash from Financing | -69.21% | -95.72% | 63.71% | 63.22% | 63.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -184.72% | -218.55% | 77.82% | 145.43% | 178.50% |